Barrington Research Raises LeMaitre Vascular (NASDAQ:LMAT) Price Target to $93.00

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) had its price target lifted by equities research analysts at Barrington Research from $92.00 to $93.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an "outperform" rating on the medical instruments supplier's stock. Barrington Research's price objective would indicate a potential downside of 1.98% from the stock's current price.

LMAT has been the subject of a number of other reports. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price objective for the company. JMP Securities lifted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 20th. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Tuesday, August 27th. Finally, Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a "buy" rating and a $105.00 price target for the company. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, LeMaitre Vascular has a consensus rating of "Moderate Buy" and a consensus price target of $94.57.

LeMaitre Vascular Stock Up 7.3 %

NASDAQ LMAT traded up $6.49 on Friday, reaching $94.88. The company had a trading volume of 343,615 shares, compared to its average volume of 123,348. The stock has a market capitalization of $2.13 billion, a PE ratio of 59.86, a price-to-earnings-growth ratio of 2.33 and a beta of 0.88. The firm's 50 day moving average price is $89.53 and its 200 day moving average price is $82.77. LeMaitre Vascular has a 12 month low of $45.96 and a 12 month high of $101.67.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $54.82 million during the quarter, compared to analysts' expectations of $53.50 million. During the same period last year, the company posted $0.33 EPS. The business's revenue was up 15.6% on a year-over-year basis. On average, research analysts expect that LeMaitre Vascular will post 1.86 EPS for the current year.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company's stock, valued at $1,158,335.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several large investors have recently added to or reduced their stakes in LMAT. Vanguard Group Inc. raised its holdings in shares of LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier's stock valued at $87,914,000 after purchasing an additional 38,303 shares in the last quarter. Norden Group LLC bought a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $401,000. BNP Paribas Financial Markets raised its stake in shares of LeMaitre Vascular by 135.6% during the 1st quarter. BNP Paribas Financial Markets now owns 22,917 shares of the medical instruments supplier's stock worth $1,521,000 after acquiring an additional 13,189 shares in the last quarter. Whitegate Investment Counselors Inc. bought a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $216,000. Finally, Texas Permanent School Fund Corp raised its stake in shares of LeMaitre Vascular by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier's stock worth $1,151,000 after acquiring an additional 225 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.